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Abstract
Conventional control and eradication strategies for bovine tuberculosis (BTB) face tremen-
dous difficulties in developing countries; countries with wildlife reservoirs, a complex wildlife-
livestock-human interface or a lack of veterinary and veterinary public health surveillance.
Vaccination of cattle and other species might in some cases provide the only suitable control
strategy for BTB, while in others it may supplement existing test-and-slaughter schemes.
However, the use of live BCG has several limitations and the global rise of HIV/AIDS infec-
tions has furthermore warranted the exploration of inactivated vaccine preparations. The
aim of this study was to compare the immune response profiles in response to parenteral
vaccination with live BCG and two inactivated vaccine candidates in cattle.
Twenty-four mixed breed calves (Bos taurus) aged 4–6 months, were allocated to one of
four groups and vaccinated sub-cutaneously with live M. bovis BCG (Danish 1331), forma-
lin-inactivated M. bovis BCG, heat-killed M. bovis or PBS/Montanide™ (control). Interferon-
γ responsiveness and antibody production were measured prior to vaccination and at
weekly intervals thereafter for twelve weeks. At nine weeks post-priming, animals were skin
tested using tuberculins and MTBC specific protein cocktails and subsequently challenged
through intranodular injection of live M. bovis BCG.
The animals in the heat-killed M. bovis group demonstrated strong and sustained cell-
mediated and humoral immune responses, significantly higher than the control group in
response to vaccination, which may indicate a protective immune profile. Animals in this
group showed reactivity to the skin test reagents, confirming good vaccine take. Lastly,
although not statistically significant, recovery of BCG after challenge was lowest in the heat-
killed M. bovis group.
In conclusion, the parenteral heat-killed M. bovis vaccine proved to be clearly immuno-
genic in cattle in the present study, urging further evaluation of the vaccine in challenge stud-
ies using virulent M. bovis and assessment of vaccine efficacy in field conditions.
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Introduction
Control of bovine tuberculosis (BTB), caused by Mycobacterium bovis (M. bovis), is urgently
needed on a global scale. The detrimental effects on the cattle industry worldwide as well as on
wildlife conservation [1] are noteworthy, with global losses of approximately $3 billion annually
[2], and BTB is furthermore of great public health concern. Although “test-and-slaughter” is the
conventional control strategy that allowed eradication of the infection in many developed coun-
tries, it has proven less effective or unaffordable in other countries facing a multitude of con-
straints [3, 4], and vaccination of cattle and other species is being considered as a possible
alternative approach to BTB control. To date, the only available vaccine is that produced with
the Bacille Calmette-Gue´rin (BCG) strain, which originated from virulent M. bovis through
attenuation and was first used in humans in 1921 [5, 6]. Live BCG is currently registered for use
in humans and badgers only [7]. Its use in cattle is prohibited in the EU [8] due to induction of
immune responsiveness that interferes with the standard diagnostic methods for BTB utilizing
tuberculins and in addition because of the widely variable degree of protection it provides.
Hence research efforts have focused on the development of diagnostic reagents that can differ-
entiate between infected and vaccinated animals (DIVA) and on potentiation of the protective
effect of BCG [8]. Different strategies using live BCG as either the priming or boosting vaccine
in combination with a viral vector [9], recombinant DNA or sub-unit vaccine formulations [10]
incorporating various Mycobacterium tuberculosis complex (MTBC) specific antigens, have
been explored, with conflicting results. Skinner et al. [11] found that the use of a DNA prime-
BCG boost regimen using plasmids encoding Hsp65, Hsp70 and Apa was able to significantly
improve protection against BTB compared to BCG alone. Likewise, a study by Vordermeier
et al. [9], showed that the efficacy of BCG seemed to improve after boosting with a formulation
of recombinant attenuated adenovirus expressing antigen 85A. However, vaccination with
MPB70 or MPB83 DNA plasmids was not found to be protective in cattle [12].
The rise of the HIV/AIDS pandemic prompted a renewed interest in killed vaccine candi-
dates for protection against tuberculosis [13], as immunocompromised individuals are at risk of
developing disseminated disease (BCG-osis) after vaccination with live BCG [10]. This is of spe-
cial importance in southern Africa, where HIV prevalence is amongst the highest in the world
[14]. In these regions, a complex wildlife-livestock-human interface furthermore increases the
risk of zoonotic transmission of infectious agents [15]. The use of an inactivated rather than a
live vaccine against BTB in cattle, would eliminate the risk of potential propagation of the vac-
cine strain in food producing animals, a concern raised by the Department of Agriculture, For-
estry and Fisheries (DAFF) in South Africa (DAFF, personal communication, November 2014).
Vaccination with formalin-inactivated BCG in a Novasome™ adjuvant conferred protection
against tuberculosis in guinea pigs [13] and subsequent evaluation in cattle by Whelan et al.
[16] demonstrated strong IFN-γ and IgG responses. Promising results of parenteral and oral
vaccination with a heat-killed Mycobacterium bovis vaccine have since been obtained in several
species [17–19]. The aim of the present study was to compare the immune response profiles in
response to the parenteral vaccination with live BCG and two inactivated vaccine candidates in
cattle. Cell-mediated and humoral immune response profiles resulting from vaccination, skin
testing and BCG challenge were monitored over time and compared to a control group.
Materials & methods
Animals
This study was carried out in strict accordance with the guidelines of the Animal Use and Care
Committee of the University of Pretoria and the protocol was approved (Certificate number
V066-15) prior to commencement of the study.
Inactivated Mycobacterium bovis vaccine candidates in cattle
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Twenty-four mixed breed Bos taurus calves (4–6 months of age; 12 males and 12 females)
from a local beef herd with a known BTB free history were used in this study. Exclusion criteria
included prior infection with M. bovis as determined by the bovine IFN-γ release assay (BOVI-
GAM1) and serological testing (IDEXX TB ELISA). All animals were subjected to a full clini-
cal examination, received prophylactic treatment to prevent parasitic and bacterial infections
and were allowed to acclimatize to their new environment at the class II biological contain-
ment holding facilities of the University of Pretoria Biomedical Research Center (UPBRC) for
a period of 6 weeks. The facilities comprised of individual stalls (physical contact between ani-
mals in adjacent stalls was not possible) that held the animals of the same vaccine group in
pairs, in a spacious, closed and well ventilated cattle holding facility. In view of maturation of
the animals in course of the experiment the animals were grouped in pairs based on their sex
and each pair was randomly allocated to a pen. Each pen was assigned to one of the treatment
groups beforehand. Animals of the four different groups were kept separated.
Experimental timeline
The experimental timeline for the study is depicted in Fig 1.
Vaccination
Calves were assigned to one of four groups (n = 6 per group). Groups 1–3 received different
vaccines and group 4 served as an unvaccinated control group. In groups 2–4, the adjuvant
Montanide™ ISA 50 V 2 (SEPPIC, France) was used; a water-in-oil adjuvant, compatible with
inactivated antigens, recommended for use in cattle. While Montanide™ stimulates both
humoral and cell-mediated immunity, it induces a milder local reaction as compared to other
adjuvants (unpublished data).
Fig 1. Experimental timeline for the study. Baseline values were established from T-4 until T0 with a sampling interval of 2–3 weeks. After
vaccination (T0) until the end of the experiment (T12), the sampling interval was 1 week. Animals were skin tested at T9, challenged with BCG at T9
+ 3 days and euthanized at T12. T(x) = time point (week number).
https://doi.org/10.1371/journal.pone.0188448.g001
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Live M. bovisBacille Calmette-Gue´rin (Group 1). Lyophilized live M. bovis BCG Danish
1331 (Statens Serum Institute, Denmark) was reconstituted with the diluent provided by the
manufacturer and made up to a concentration of approximately 2 x 106 CFU per ml. One mil-
liliter was administered subcutaneously in the left mid cervical area to all animals in group 1 at
T0.
Formalin-inactivated M. bovisBacille Calmette-Gue´rin (Group 2). The formalin-inacti-
vated M. bovis BCG vaccine was prepared as previously described [13], with a 50% reduction
in the formalin treatment time. Briefly, reconstituted live M. bovis BCG Danish 1331 were sus-
pended in 1.5% formalin (v/v) in phosphate buffered saline (PBS) (Sigma-Aldrich, South
Africa). The suspension was stirred continuously at 4˚C for 48h and subsequently centrifuged
at 14,000 x g for 15 minutes at 4˚C. The cells were then washed twice, resuspended in sterile
PBS to a concentration of 4 x 107 cells/ml and stored at 4˚C until use (no longer than three
days). Successful inactivation of the BCG was demonstrated by inoculation of aliquots of the
vaccine on Lo¨wenstein-Jensen (LJ) slants enriched with pyruvate, followed by incubation for
10 weeks. No growth was observed. The vaccine consisted of formalin-inactivated BCG and
Montanide™ ISA 50 V 2 (SEPPIC, France) adjuvant carefully emulsified and made up to a con-
centration of 2 x 107 cells/ml. One milliliter was administered subcutaneously in the left mid
cervical area to all animals in group 2 at T0 and again at T3 (booster).
Heat-killed M. bovis (Group 3). The heat-killed M. bovis vaccine was prepared as previ-
ously described [17]. The vaccine consisted of heat-inactivated M. bovis (Neiker strain) and
Montanide™ ISA 50 V 2 (SEPPIC, France) adjuvant carefully emulsified and made up to a con-
centration of 1 x 107 CFU/ml. One milliliter was administered subcutaneously in the left mid
cervical area to all animals in group 3 at T0 and again at T3 (booster).
Control group inoculum (Group 4). Phosphate buffered saline (Sigma-Aldrich, South
Africa) and 50% Montanide™ ISA 50 V 2 (SEPPIC, France) adjuvant (v/v) were carefully emul-
sified to serve as an inoculum for the control group. One milliliter was administered subcuta-
neously in the left mid cervical area to all animals in group 4 at T0.
Sample collection
Whole blood was collected from the jugular vein using a vacutainer system at several time
points prior to vaccination for the BOVIGAM1 assay and IDEXX TB ELISA and outcomes
were averaged in order to establish baseline values. Thereafter whole blood samples were col-
lected every week for a total of twelve weeks (Fig 1).
Bovine IFN-γ release assay
Heparinized whole blood samples from all calves were individually processed within 2–3 hrs
after collection. Antigen stimulations for the BOVIGAM1 assay were carried out in 48-well
cell culture plates (Cellstar1 Greiner Bio One, Germany) as previously described [20]. At each
time point, undiluted heparinized blood was aliquoted into 1 ml per well and stimulated with
pokeweed mitogen (PWM; 5 μg/ml) as a positive sample control, PPD-B (purified protein
derivative of M. bovis; 600 IU/ml), PPD-A (purified protein derivative of M. avium; 1000 IU/
ml) and PPD-F (purified protein derivative of M. fortuitum; 28.5 μg/ml, ARC-Onderstepoort
Veterinary Institute) [19]. One aliquot of whole blood was left unstimulated to serve as a nega-
tive control. At three time points (T0, T3 and T9), additional aliquots of whole blood were
stimulated with the recombinant mycobacterial proteins ESAT-6 (5 μg/ml) and CFP-10 (5 μg/
ml) (LIONEX GmbH, Germany). The samples were incubated at 37˚C for 20 hrs, after which
supernatants were harvested. Interferon-γ detection was carried out according to the manufac-
turer’s protocol (Thermo Fisher Scientific, South Africa). Criteria for sample validity were an
Inactivated Mycobacterium bovis vaccine candidates in cattle
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optical density value (OD) 0.45 for PWM and OD 0.35 for the negative control (ODneg).
Responses elicited by TB antigens were corrected by subtracting the OD-value of the negative
control (ODbov minus ODneg, ODav minus ODneg, ODfort minus ODneg, ODESAT6 minus
ODneg and ODCFP10 minus ODneg).
Serology
Blood samples were collected without anticoagulants and left to clot overnight at ambient tem-
perature. Sera were harvested the next day and subsequently tested for the presence of M. bovis
specific antibodies with the IDEXX TB ELISA, using a 1:50 dilution of the samples and con-
trols, according to the manufacturer’s protocol (IDEXX, USA). Criteria for the test validity
were an OD 0.3 for the positive control and OD 0.2 for the negative control. Sample/posi-
tive control (S/P) ratios were calculated according to the manufacturer’s protocol.
Skin test
At T9, the skin test was performed according to OIE [21] recommendations, with the addition
of two protein cocktails alongside the standard tuberculins. Briefly, hair was clipped at 4 sites
on the left mid-cervical region that were injected intradermally with 0.1 ml of PPD-B (30,000
IU/ml), PPD-A (25,000 IU/ml), protein cocktail 1 (PC1; containing 10 μg/ml of ESAT-6, CFP-
10 and Rv3615c each) and protein cocktail 2 (PC2; containing 10 μg/ml of ESAT-6, CFP-10,
Rv3615c and Rv3020c each) [22], respectively. After 72 hrs the injection sites were inspected
and palpated for signs of a delayed-type hypersensitivity reaction and the skin fold thickness
measured to calculate the difference (Δmm) between pre-injection (0hrs) and post-injection
(72hrs) measurements. Differences in increase of skin fold thickness of4 mm between the
bovine and avian injection sites and/or the presence of typical clinical signs (necrosis, edema,
heat, pain) in combination with a lower increase were considered positive skin test reactions; a
difference of 2–4 mm between bovine and avian injection sites was considered a suspect result;
while a difference of0 to 2 mm between bovine and avian injection sites was considered a
negative skin test. The reactions to the protein cocktails were interpreted according to Jones
et al. [22]; an increase in skin fold thickness of 1 mm was considered positive.
Intranodular BCG challenge
As an alternative challenge approach, the animals were inoculated in the right prescapular lymph
node with live M. bovis BCG Danish 1331 at T9 + 3 days (after reading of the skin test). This
approach has previously been shown to be a viable alternative to challenge with pathogenic M.
bovis without the need for biosafety level 3 facilities [23] to serve as a preliminary evaluation of
protection. Briefly, the lyophilized live M. bovis BCG Danish 1331 vaccine strain was reconstituted
in the diluent provided by the manufacturer (Statens Serum Institute, Denmark), inoculated on
LJ slants containing pyruvate and incubated for 4 weeks at 37˚C. A challenge inoculum was pre-
pared through suspension of the fresh mycobacterial culture in PBS to a concentration of 2 x 108
CFU/ml and 1 ml was injected. At T12 the animals were euthanized by means of a captive bolt
and the left (control) and right (inoculated) prescapular lymph nodes were harvested.
Mycobacterial culture
The weights of the prescapular lymph nodes, collected at T12, were measured to assess inflam-
mation and cellular congestion. Each sample was weighed and inspected for the presence of
lesions. In the absence of lesions, a representative sample of ± 2 g from the center of each
lymph node (the site of BCG inoculation) was collected aseptically for culture. The samples
Inactivated Mycobacterium bovis vaccine candidates in cattle
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were homogenized in a final volume of 7 ml sterile distilled water and decontaminated with an
equal volume of 2% hydrogen chloride (HCl) during 10 minutes. The samples were then cen-
trifuged at 2550 x g for 10 minutes and the supernatant discarded. Subsequently the samples
were resuspended in 7 ml of sterile distilled water and centrifuged at 2550 x g for 10 minutes,
in order to remove remaining HCl. The supernatant was discarded and the pellet resuspended
in 3 ml of distilled water and inoculated onto LJ slants containing pyruvate and incubated at
37˚C for 10 weeks. Bacterial counts were determined as CFU per gram of lymph node.
Confirmation of mycobacterial growth as being M. bovis BCG was done using the polymer-
ase chain reaction (PCR) targeting the regions of difference (RD) RD1, RD4 and RD9 as previ-
ously described [24].
Data analysis
Statistical analyses of the data gathered in this study were conducted in R version 3.3.0 [25], as
described below.
Bovine IFN-γ release assay. A linear mixed effects model [26] was used to analyze the
results of the BOVIGAM1 assay in the different groups as compared to the control group. For
analysis of PPD-B, PPD-B/PPD-A, PPD-B/PPD-F, ESAT-6 and CFP-10, data were log trans-
formed, after adding 0.5, 0.5, 0.75, 0.05 and 0.05 to each value of the outcome variable (to
achieve positive values), respectively, to meet the model assumptions of normality and homo-
scedasticity. Explanatory variables were time, vaccination group and the interaction between
both, which proved to be the final model. A variance function was added to the models of
PPD-B, ESAT-6 and CFP-10 to allow for different standard deviations in the vaccination
groups. Correlated observations within animals were accounted for by using a random inter-
cept and slope for the animal ID. The Akaike Information Criterion (AIC) was used to select
the best model.
Serology. A linear mixed effects model [26] was used to analyze the results of the IDEXX
TB ELISA in the different groups as compared to the control group. For analysis of the S/P
ratio data were log transformed, after adding 0.1 to each value of the outcome variable (to
achieve positive values), to meet the model assumptions of normality and homoscedasticity.
The other criteria and parameters of the model were the same as for the model of PPD-B.
Skin test. In order to account for the heteroscedasticity of the variances, a double general-
ized linear model [27] was used to analyze the skin reactions to the tuberculins (ΔPPD-B minus
ΔPPD-A in mm). A simple general linear model was used to analyze the skin reactions to the
protein cocktails (ΔPC1 and ΔPC2 in mm). The explanatory variable was vaccination group.
Intranodular BCG challenge. Prescapular lymph node weights in the treatment groups
were compared to the control group using a linear mixed effects model [26]. The outcome var-
iable was log transformed to meet the model assumptions of normality and homoscedasticity.
Explanatory variables were lymph node side, vaccination group, the interaction between both
and gender which proved to be the final model. Correlated observations within animals were
accounted for by using a random intercept and slope for the animal ID.
A negative binomial generalized linear model was used to compare the bacterial counts
from the right prescapular lymph nodes of the treatment groups to the control group. The
explanatory variable was vaccination group.
Results
Bovine IFN-γ release assay
Cell-mediated immunity (CMI) as a consequence of vaccination with the different vaccines
was monitored by means of IFN-γ responses using the BOVIGAM1 assay for nine weeks
Inactivated Mycobacterium bovis vaccine candidates in cattle
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(T1-T9) in all animals and compared to the control group. Interferon-γ responses following
skin test and BCG challenge (at T9 and T9 + 3 days, respectively) were monitored for two
weeks (T10-T11). One animal from the formalin-inactivated BCG group was excluded from
this analysis due to unresponsiveness of white blood cells to stimulation with PWM from T1 to
T9. The PPD-B specific IFN-γ responses (corrected for the ODneg), expressed as OD values
(ODbov), in the four treatment groups over time are presented in Fig 2A. The response to
PPD-B was analyzed using a linear mixed effects model [26] and compared to the control
group (Table A in S2 Dataset). The mean (n = 6) responses to PPD-B prior to vaccination (T0)
were below an OD-value of 0.5 for all groups. Mean OD-values for PPD-B in the control
group ranged from 0.311 to 0.820 after vaccination (T1-T9). A similar trend was observed in
the formalin-inactivated BCG group, with slightly lower mean ODbov values ranging from
0.275 to 0.594 and no significant differences to the control group. The live BCG group showed
slightly elevated mean ODbov values as compared to the control group in response to vaccina-
tion (T1-T9), ranging from 0.802 to 1.353, and differences were significant at T4 only (Table A
Fig 2. Interferon-γ responses in the BOVIGAM® assay. Mean OD-values in response to (A) PPD-B, (B) PPD-B minus PPD-A, (C) PPD-B minus PPD-F,
(D) ESAT-6 and (E) CFP-10. ● = Live M. bovis BCG;  = Formalin-inactivated BCG;▲ = Heat-killed M. bovis;4 = Control group. Error bars indicate the
standard error of the mean (±SEM) for each time point. Arrows at T0, T3 and T9 indicate priming vaccination, booster vaccination and SICTT and BCG
challenge, respectively.
https://doi.org/10.1371/journal.pone.0188448.g002
Inactivated Mycobacterium bovis vaccine candidates in cattle
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in S2 Dataset). The heat-killed M. bovis group showed the highest ODbov values after vaccina-
tion, ranging from 1.996 to 3.374, peaking at T4, and significant differences compared to the
control group were observed from early on in the experiment and were sustained up to and
including T9 (Table A in S2 Dataset). After skin test and BCG challenge, the mean ODbov val-
ues were elevated as compared to T9 in all groups except the heat-killed M. bovis group. In the
control group, mean ODbov values ranged from 1.833 to 1.953. No significant differences to
the control group were found in the live BCG and heat-killed M. bovis groups, with mean
ODbov values ranging from 2.296 to 2.578 and 2.349 to 2.903, respectively. In the formalin-
inactivated group ODbov values ranged from 0.793 to 1.014 and this was significantly lower as
compared to the control group at T11 (Table A in S2 Dataset).
Reactivity to two predominant environmental mycobacteria (M. avium and M. fortuitum)
was taken into account in the analysis of the IFN-γ responses and presented as ODbov-ODav and
ODbov-ODfort (both corrected for the ODneg) in Fig 2B and 2C, respectively. The ratios of
PPD-B/PPD-A and PPD-B/PPD-F were analyzed using a linear mixed effects model [26] and
compared to the control group (Table A in S2 Dataset). In the PPD-B/PPD-A model, both the
live and the formalin-inactivated BCG vaccination groups showed no significant differences
when compared to the control group. In the heat-killed M. bovis group, however, responses sig-
nificantly higher as compared to the control group were observed at several time points (T4-T9)
after vaccination (Table A in S2 Dataset). In the PPD-B/PPD-F model, the immune responses in
the live and formalin-inactivated BCG groups were largely comparable to those in the control
group, but differences significantly higher as compared to the control group were seen in the live
BCG group at T6 (Table A in S2 Dataset). Again, the heat-killed M. bovis group showed signifi-
cantly higher responsiveness as compared to the control group at multiple time points (T1 and
T3-T9) after vaccination as well as after skin test and challenge (T10) (Table A in S2 Dataset).
In addition to the classical PPDs as stimulating antigens in CMI testing, ESAT-6 and CFP-
10, two antigens widely used in TB research and diagnosis, as they are assumed to be specific
for the MTBC, were included in the BOVIGAM1 assay at T0, T3 and T9. Fig 2D and 2E pres-
ent the IFN-γ responses specific to these antigens in the four vaccination groups during the
course of the experiment. The responses to ESAT-6 and CFP-10 were analyzed using a linear
mixed effects model [26] and compared to the control group (Table B in S2 Dataset). One ani-
mal in the heat-killed M. bovis group showed an extremely high value at week 9 and this entry
was excluded from the model. Mean OD-values for ESAT-6 (ODESAT6) in the control group
ranged from -0.026 to 0.064. Similar trends were observed in the other vaccination groups
with OD ESAT6 values ranging from -0.034 to 0.011 (live BCG), from -0.049 to 0.022 (formalin-
inactivated BCG) and from -0.019 to 0.094 (heat-killed M. bovis). There were no significant
differences in the responses to ESAT-6 in any of the vaccination groups as compared to the
control group (Table B in S2 Dataset). Mean OD-values for CFP-10 (ODCFP10) in the control
group ranged from -0.021 to 0.016. Similar trends were observed in the vaccination groups
receiving the live and formalin-inactivated BCG vaccines with ODCFP10 values ranging from
-0.023 to 0.036 and from -0.047 to 0.034, respectively. The mean response to CFP-10 in the for-
malin-inactivated BCG group was significantly lower as compared to the control group at T9
(Table B in S2 Dataset). Mean ODCFP10 values in the heat-killed M. bovis group showed a slight
increase as compared to the control group ranging from -0.008 to 0.462 at T3 and from 0.001
to 0.557 at T9, and these were significantly different (Table B in S2 Dataset).
Serology
Humoral immune (HI) responsiveness to the different vaccine candidates was monitored for
nine weeks (T1-T9) in all animals and compared to the control group. Responses following
Inactivated Mycobacterium bovis vaccine candidates in cattle
PLOS ONE | https://doi.org/10.1371/journal.pone.0188448 November 20, 2017 8 / 20
skin test and BCG challenge (at T9 and T9 + 3 days, respectively) were monitored for further
three weeks (T10-T12). Fig 3 presents the mean S/P ratios for the vaccination groups over
time. The S/P ratios were analysed using a linear mixed effects model [26] and compared to
the control group (Table C in S2 Dataset). Prior to vaccination, the mean S/P ratios in all
groups were approximately -0.04. Mean S/P ratios in the control group ranged from -0.022 to
0.007 after vaccination (T1-T9). Humoral responses after vaccination in the groups receiving
the live and formalin-inactivated BCG preparations mirrored those in the control group (Fig
3) and thus no significant differences to the control group were found (Table C in S2 Dataset).
In the heat-killed M. bovis group, a humoral response was detected from as early as T2, which
increased and was sustained during the course of the experiment (Fig 3), with values ranging
from 0.003 to 9.213 after vaccination (T1-T9). The S/P ratios in this group were found to be
significantly higher compared to those in the control group at several time points (T2-T9)
(Table C in S2 Dataset). After skin testing and BCG challenge (at T9 and T9 + 3 days, respec-
tively), mean S/P ratios in the control group showed a very slight increase, ranging from 0.086
to 0.245. In contrast, there appeared to be no response to skin test and BCG challenge in the
Fig 3. Antibody responses in the IDEXX TB ELISA. Mean sample/positive (S/P) ratios. ● = Live M. bovis BCG;  = Formalin-inactivated BCG;▲ = Heat-
killed M. bovis;4 = Control group. Error bars indicate the SEM for each time point. Arrows at T0, T3 and T9 indicate priming vaccination, booster vaccination
and SICTT and BCG challenge, respectively.
https://doi.org/10.1371/journal.pone.0188448.g003
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formalin-inactivated BCG group and S/P ratios ranged from 0.027 to 0.067. The S/P ratios
observed in the live BCG group at time points T10 to T12 were significantly higher than in the
control group (Table C in S2 Dataset). The S/P ratios in the heat-killed M. bovis group pla-
teaued at a value of 10.663 after skin test and BCG challenge and these values were significantly
higher than the control group (Table C in S2 Dataset). The plateau effect was considered a con-
sequence of the ELISA reader’s upper detection limit rather than a true reflection of the optical
density.
Skin test
The skin test was carried out on all animals in all groups. The difference between the increase
in skin fold thickness in reaction to PPD-A was deducted from that to PPD-B and presented in
Fig 4A, while the reactions to the two protein cocktails PC1 and PC2 are presented in Fig 4B
and 4C. A double generalized linear model was used to analyze the reaction to the tuberculins
(Table D in S2 Dataset), whereas the reactions to the PC1 and PC2 were analyzed using a sim-
ple general linear model (Table E in S2 Dataset).
Fig 4. Results of the skin test. Differences in skin fold thickness (A) between PPD-B and PPD-A, (B) of protein cocktail 1 and (C) of protein cocktail 2.
ΔPPDB is the difference in skin fold thickness at the PPD-B injection site between 72 hrs (post injection) and 0 hrs (pre-injection). ΔPPDA is the difference in
skin fold thickness at the PPD-A injection site between 72 hrs (post injection) and 0 hrs (pre-injection). Δmm is the difference in skin fold thickness of the
injection site between 72 hrs (post injection) and 0 hrs (pre-injection).
https://doi.org/10.1371/journal.pone.0188448.g004
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The difference in increase of skin fold thickness in reaction to the tuberculins (Δmm of
PPD-B minus Δmm PPD-A) ranged from -4.0mm to -1.0mm in the control group and as such
all animals in this group were characterized as negative reactors. Animals in the formalin-inac-
tivated BCG group showed similar reactions to the PPDs as the control group (differences in
increase of skin fold thickness ranged from -2.8mm to -0.1mm), and no significant differences
as compared to the control group were found and all animals were characterized as negative
reactors (Table D in S2 Dataset). In the live BCG group, the differences in increase of skin fold
thickness ranged from 0.1mm to 2.8mm, and these reactions were found to be significantly
higher as compared to the control group (Table D in S2 Dataset). In this group, 1/6 animals
was classified as a positive reactor (Δmm of 2.8 and edema) and 1/6 animals was classified as a
suspect reactor. In the heat-killed M. bovis group the differences in increase of skin fold thick-
ness ranged from -1.0mm to 10.2mm, and these reactions were found to be significantly higher
as compared to the control group (Table D in S2 Dataset). In this group, 3/6 and 2/6 animals
were classified as positive and suspect reactors, respectively.
No animals in the control group showed reactions to PC1 and PC2 and the differences
(Δmm 72 hrs and 0 hrs) ranged from -0.1mm to -0.4mm and from -0.7mm to 0.5mm, respec-
tively, and animals were characterized as negative reactors. In the live and formalin-inactivated
BCG groups, reactions to PC1 and PC2 were slightly elevated as compared to the control
group, but no significant differences to the control group were found (Table E in S2 Dataset).
In the heat-killed M. bovis group, the reactions were significantly elevated as compared to the
control group and the differences in skin fold thickness ranged from 1.8mm to 3.6mm for PC1
and from 0.0mm to 2.3mm for PC2 (Table E in S2 Dataset). In this group, 6/6 and 3/6 animals
were classified as positive reactors to PC1 and PC2, respectively.
Intranodular BCG challenge
Overall, the weights of the untreated left prescapular lymph nodes (PLNs) showed less variabil-
ity as compared to those of the right prescapular lymph nodes, which were inoculated with
BCG at T9 + 3 days. In the control group the median and interquartile range (IQR) of the left
and right prescapular lymph nodes reflect this pattern (median PLNleft = 15.29g; IQR PLNleft =
3.67g; median PLNright = 14.49g; IQR PLNright = 6.18g). The lymph nodes of the animals in the
live BCG group, however, showed lower weights and less variability (median PLNleft = 14.14g;
IQR PLNleft = 1.65g; median PLNright = 13.96g; IQR PLNright = 1.57g). In the formalin-inacti-
vated BCG group the median and interquartile range was slightly elevated compared to the
control group (median PLNleft = 16.58g; IQR PLNleft = 3.20g; median PLNright = 16.14g; IQR
PLNright = 5.67g). The weights of the PLNs were highest and showed the most variability in the
heat-killed M. bovis group (median PLNleft = 18.42g; IQR PLNleft = 3.69g; median PLNright =
16.29g; IQR PLNright = 8.06g). No significant differences to the control group were found for
either lymph node side in any of the groups when analyzed using a linear mixed effects model
[26] (Table F in S2 Dataset).
Culture and M. bovis PCR
Growth of mycobacteria was not observed in cultures of any of the left prescapular lymph
nodes and these were omitted from this analysis. Mycobacterial growth was detected in cul-
tures of the right prescapular lymph nodes of 3/6 animals in the live BCG group, 5/6 animals
in the formalin-inactivated BCG group, 5/6 animals in heat-killed M. bovis group and 2/6 of
the control animals.
PCR confirmed presence of M. bovis BCG in all isolates (S1 Fig). In the right prescapular
lymph nodes, the highest bacterial counts (CFU/gram) were found in the live BCG group
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(range = 0–6650), followed by the formalin-inactivated BCG group (range = 0–3402), the con-
trol group (range = 0–574) and the heat-killed M. bovis group (range = 0–182) (Fig 5). The
heat-killed M. bovis group was found to have lower bacterial counts (estimate ratio = 0.730) as
compared to the control group, but this difference was not significant (Table G in S2 Dataset).
Additionally, although bacterial counts were higher in the live BCG group (estimate ratio =
11.345) and formalin-inactivated BCG (estimate ratio = 9.075) group, these were not signifi-
cantly different to the control group (Table G in S2 Dataset).
Discussion
The present study aimed at characterization and evaluation of immune response profiles
induced in calves by inactivated Mycobacterium bovis vaccine candidates as compared to live
BCG and a control inoculum. This immunogenicity study is an important step in the process
of evaluation of a new vaccine candidate, before execution of controlled field trials, to assess
protective efficacy against BTB in cattle.
Fig 5. Log transformed bacterial counts (CFU/gram) of the right prescapular lymph nodes. The data was log transformed to accommodate for the
large variance. As several lymph nodes had shown no growth, equal to bacterial count = 0, +1 was added to all values to allow for log transformation.
https://doi.org/10.1371/journal.pone.0188448.g005
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The live BCG and formalin-inactivated BCG groups did not exhibit pronounced CMI
responses. In the heat-killed M. bovis group, however, strong and sustained IFN-γ responses to
PPD-B were detected that, even when accounting for possible cross-reactivity due to exposure
to non-tuberculous mycobacteria (Fig 2A–2C), were significantly higher as compared to the
control group. Furthermore, an elevated response to CFP-10, significantly different to the con-
trol group, in the heat-killed M. bovis group at T3 and T9, pointed to a cell-mediated immune
response believed to be specific to species of the MTBC. Surprisingly, no response to ESAT-6
was detected in this group. Since CFP-10 and ESAT-6 are found on the region of difference 1
(RD1) gene region of M. bovis [28] and are co-transcribed [29], it was expected that animals in
the heat-killed M. bovis group would show reactivity, of comparable magnitude, to both pro-
teins. However, heat-inactivation of the M. bovis strain used in this vaccine at 80˚C for 30 min-
utes [17], may have affected these proteins differently and could explain the lack of a response
to ESAT-6. Although the exact underlying processes remain unclear, IFN-γ release in response
to M. bovis specific antigenic stimulation after vaccination is generally accepted to play an
important role in the protective mechanism against BTB, emphasizing the role of cell-medi-
ated immunity. This role was confirmed in an ‘ex vivo’ experiment carried out by Juste et al.
[19] which determined that bovine macrophages trained with the heat-killed M. bovis vaccine
through intramuscular injection exhibited an increased lytic capacity, which was furthermore
proposed as an underlying mechanism of vaccine protection. Moreover, a study in wild boar
confirmed that high IFN-γ responses to PPD-B after vaccination with heat-killed M. bovis are
likely to contribute to the protective mechanisms against BTB [17, 30]. Likewise, the CMI
responses detected in the heat-killed M. bovis group in the present study, may point towards a
similar protective mechanism in cattle.
In the present study, an early and progressively increasing humoral immune response to
the heat-killed M. bovis vaccine, significantly different from the control group, was found as
well (Fig 3). There was no evidence of an HI response in the live BCG and formalin-inactivated
groups. The role of humoral immunity in protection against bovine tuberculosis and as a
parameter for vaccine efficacy is not particularly well understood and previous studies have
demonstrated conflicting results. Wedlock et al. [12] described that significant humoral
responses to a MPB70 DNA and protein vaccine regimen could not confer protection in cattle.
In contrast, studies using inactivated BCG preparations in mice by Haile et al. [31] illustrated
significant antibody responses and their vaccine was more efficacious than live BCG. The
importance of an antibody response in mycobacterial infections has furthermore been high-
lighted in a study evaluating post-exposure vaccination against paratuberculosis and a cor-
relation with vaccine efficacy was established [32]. The heat-killed M. bovis vaccine elicited
antibody responses in wild boar that were suggested to be associated with protection against
BTB [17, 30]. The strong HI response detected in the present study could potentially play a
role in a protective mechanism against mycobacteria.
The IFN-γ response to stimulation with PPD-B increased in both BCG groups as well as the
control group after skin test and BCG challenge. As strong post-challenge IFN-γ responses are
commonly associated with a higher lesion burden and lower vaccine efficacy against bovine
tuberculosis, previously demonstrated by Hope et al. [33], the present findings may suggest that
these vaccinates would not be protected. In contrast, in the heat-killed M. bovis group an initial
decline followed by resurgence of the IFN-γ response was seen from T10-T11, but it remained
below levels observed prior to T10. The fact that post-challenge IFN-γ responses were lowest in
this group, strengthens the proposition that the heat-killed M. bovis vaccine appears to elicit a
CMI response which may confer protection against BTB in cattle. In tuberculous pleuritis in
humans, localized rather than systemic action of the cell-mediated immune response, associated
with higher proportions of IFN-γ secreting lymphocytes in the pleural cavity as compared to the
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blood, has been demonstrated by several research groups [34, 35] and is suggested to be respon-
sible for mycobacterial clearance without therapeutic intervention [36]. The decline in PPD-B
specific CMI responses in peripheral blood after challenge in the heat-killed M. bovis group,
could possibly be a result of homing of memory T cells to the site of the challenge, depleting
such cells from the periphery. Evaluation of lymphocytes present in the inoculated prescapular
lymph nodes would be required to test this hypothesis and was beyond the scope of the current
study. Assessment of the weights and bacterial counts of these lymph nodes did, however, show
that the weight distribution was the most variable in the heat-killed M. bovis group, while the
bacterial counts were lowest in this group. These findings might potentially be a result of vari-
able influx of T-cells and subsequent increased bactericidal activity.
Animals in the control group showed no reactivity to any MTBC specific reagents used in
the skin test, confirming that these animals had not been vaccinated with or exposed to Myco-
bacterium bovis. Skin test reactivity to the tuberculins and protein cocktails in the heat-killed
M. bovis group was significantly different to the control group, clearly indicating the immuno-
genicity of this candidate. The slightly lower significance found in this group compared to that
of the live BCG group can be explained by the greater variance that was found in the differ-
ences in skin fold thickness in the heat-killed M. bovis group. The skin test is a highly impor-
tant and widely-used diagnostic tool for bovine tuberculosis. Live BCG vaccination is known
to interfere with diagnostic tests based on the use of tuberculin [37] and although in our study
the immunogenicity of live BCG appeared to be low, reactivity to bovine and avian tuberculin
in this group was significantly higher as compared to the control group. The protein cocktails,
however, contain known immunogenic proteins both present in (ESAT-6 and CFP-10) or
dependent on (Rv3615c) the RD1 region of M. bovis which is deleted from BCG [38, 39], or
proteins present in both M. bovis and BCG but with differential recognition (Rv3020) [40] and
have been developed with the aim of establishing a DIVA principle for BTB [22]. As expected,
skin test reactions in the live and formalin-inactivated BCG groups were negligible, whereas
the heat-killed M. bovis vaccine group showed significant skin test reactivity to the tuberculins
as well as the protein cocktails. It is interesting to note that although all animals tested positive
to PC1, only 3/6 tested positive to PC2. Jones et al. [22] described that the addition of Rv3020
to the cocktail of ESAT-6, CFP-10 and Rv3615c (PC1) increased sensitivity whilst preserving
specificity. In the present study, however, it appears that the sensitivity of PC2 is much lower
than that of PC1 and it is unclear what the cause of this discrepancy is.
There was no change in the humoral response post-skin test and -challenge in the control
group. As the experiment was terminated 3 weeks post-challenge, this is not surprising because
the antibody response to mycobacterial infection is known to be a marker of chronic or late-
stage of disease [41]. This, in combination with the low immunogenicity of this vaccine as
demonstrated in the current study, might also explain the lack of a response in the formalin-
inactivated BCG group. There was a moderate antibody response in the live BCG group,
which could indicate that priming of these animals to M. bovis might have been successful, but
it is questionable whether this would have been protective. Animals in the heat-killed M. bovis
group appeared to respond to the skin test and BCG challenge with a rapid deployment of M.
bovis specific antibodies as indicated by a marked increase in S/P ratio after T9, which is indic-
ative of clear sensitization to M. bovis through the initial vaccination and booster vaccine and
might be suggestive of a protective response.
Recovery of BCG after challenge
The greater variability that was found in the right prescapular lymph node weights compared
to those of the left PLNs can be explained by the fact that the challenge was performed through
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intranodular injection into the right PLN, which showed transient visible swelling and tender-
ness post-injection, whereas there was no intervention in the left PLN. It is interesting to note
that the greatest variability of PLN weights was found in the heat-killed M. bovis group. The
meaning of this is not certain and could be due to increased activity of the immune system
clearing up infection, or inflammation due to the presence of live mycobacteria. To further
investigate the outcome of the challenge, all PLNs were processed for mycobacterial culture.
The fact that M. bovis BCG could not be detected in any of the left PLNs, indicates that myco-
bacteria were not disseminated throughout the host, in line with the rationale proposed by Vil-
larreal-Ramos et al. [23]. The recovery of BCG from the right PLNs proved more challenging
than expected as the right PLNs of 4/6 of the control animals did not yield BCG on culture and
2/6 in this group showed the lowest yield of all vaccination groups. In fact, overall the bacterial
counts were highly variable within and between groups. These findings might be attributable
to the generally highly variable efficacy of BCG, documented in both animals and humans, or
to some extent due to animal to animal variation or exposure to NTM. It is noteworthy that
although recovery of BCG was successful in more animals in the formalin-inactivated BCG
and heat-killed M. bovis groups, the concentration of bacteria was lowest in the latter group.
Furthermore, although no significant differences were found, the bacterial counts in the heat-
killed M. bovis group were lower as compared to unvaccinated animals (estimate ratio = 0.73).
In contrast, the bacterial counts in the live and formalin-inactivated BCG groups were higher.
These findings suggest that live BCG was able to replicate to a lesser extent in animals vacci-
nated with heat-killed M. bovis.
Low immunogenicity of BCG vaccine formulations
Although highly variable, vaccination with live BCG has previously been found to elicit cell-
mediated immune responses in cattle and to some extent provide protection against bovine
tuberculosis [42, 43]. In the present study, including it as benchmark vaccine, live BCG did not
induce significant cell-mediated immune responses as compared to the control group. Relatively
poor immunogenicity of the vaccine, in the sense of M. bovis directed CMI responsiveness, may
have partly been caused by prior exposure to NTM [44, 45], which was reflected by the elevated
PPD-A and PPD-F responses (Fig 2B and 2C). Interestingly, animals in the heat-killed M. bovis
group were able to mount a cell-mediated immune response strongly biased towards M. bovis,
possibly suggesting that prior exposure to NTM might not interfere with the response elicited
by this inactivated vaccine formulation. If true, this could be of high importance for countries
with high prevalences of both BTB and NTM, including South Africa [44, 46].
In the present study, the results found by Whelan et al. [16] could not be reproduced as
cell-mediated and humoral immune responses detected in calves in the formalin-inactivated
BCG group were similar to or below those in the control group. The discrepancy in findings
may be due to the effects of certain critical variables on the study outcome rather than poor
reproducibility and warrant further investigation. Variables which differed between the two
studies included the use of a different adjuvant, the length of formalin treatment, the use of a
different strain of BCG and/or disparate exposure to different environmental mycobacteria.
Furthermore, as live BCG proved to show poor immunogenicity in the present study, it is
to be expected that a killed preparation of the same strain would have a similar or lower
immunogenicity.
Limitations of the study
One of the limitations of this study was that challenge with virulent M. bovis was not possible
and it is recommended that in future studies this is carried out in order to empirically assess
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pathological changes as a function of vaccine efficacy of the heat-killed M. bovis vaccine
candidate.
The use of multiple statistical models increases the chance of observing a significant result.
However, we believe that the significant results described in this study are not only statistically
but also biologically relevant. The wide confidence intervals that were found in several analyses
carried out in this study, can be explained by the fact that a relatively low number of animals
was used, which was the main limitation of the current study. Nevertheless, strong evidence
for a high immunogenicity of the heat-killed M. bovis vaccine was demonstrated which justifies
further vaccine trials to evaluate its usefulness in future BTB control strategies.
Lastly, our results indicate that there was exposure to environmental mycobacteria during
the course of the experiment, as demonstrated by the responses to PPD-A and PPD-F in the
BOVIGAM1 assay, as well as PPD-A reactivity in the skin test. The true M. bovis specific
effects of vaccination might be masked by this responsivity. However, it is important to note
that non-tuberculous mycobacteria occur ubiquitously in the environment on a global scale.
Therefore, it is promising that the heat-killed M. bovis vaccine performed well under these cir-
cumstances, as they should closely resemble field conditions.
Conclusion
The results obtained in the present study clearly indicate that subcutaneous vaccination with
the heat-killed Mycobacterium bovis vaccine elicits strong and sustained cell-mediated and
humoral immune responses in cattle, indicating excellent immunogenicity of the vaccine.
Although exact correlates of protection are not known and this remains an important point of
discussion between research groups, it may be assumed that an IFN-γ response such as dem-
onstrated in this study, forms part of the protective immune profile against BTB. The role of
humoral immunity in providing protection against BTB is even less well established, but more
evidence is becoming available suggesting its value. Therefore, the finding of both strong CMI
and HI responses to the heat-killed M. bovis vaccine, in combination with a lesser degree of M.
bovis BCG replication after challenge, highlights the potential of this vaccine candidate. In fur-
ther studies, challenge with virulent M. bovis is recommended as well as assessment of the vac-
cine in field studies to further evaluate vaccine efficacy under natural conditions.
Supporting information
S1 Fig. Conventional PCR for the detection of Mycobacterium bovis. PCR targeting RD1,
RD4 and RD9 as previously described. PCR products of +- 268bp (RD4 absent), +- 196bp
(RD1 absent) and +- 108bp (RD9 absent) indicate M. bovis BCG. Animals 18, 21 and 31 belong
to group 1 (live M. bovis BCG), animals 2, 6, 7, 16 and 29 belong to group 2 (formalin-inacti-
vated M. bovis BCG), animals 8, 9, 10, 11 and 26 belong to group 3 (heat-killed M. bovis) and
animals 12 and 15 belong to group 4 (control). R = right prescapular lymph node.
(TIF)
S1 Dataset. Tables containing the raw data of the immunological assays. (A) BOVIGAM
assay. OD-values for all stimulations and controls. (B) IDEXX TB ELISA. OD-values for the
samples and controls as well as S/P-ratio. (C) Skin test. Skin fold thickness measurements at
0hrs, 72hrs and the difference (Δmm) in mm. Avian = PPD-A; Bovine = PPD-B; PC1 = protein
cocktail 1; PC2 = protein cocktail 2. (D) Culture. Weights (g) and bacterial counts (CFU/g of
PLN) of left and right PLNs.
(XLSX)
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S2 Dataset. Tables describing the statistical models and their outcomes. (A) Linear mixed
effects models describing PPD-B and the ratios of PPD-B/PPD-A and PPD-B/PPD-F. Out-
come = a + b1  time + b2  group + b3  (time  group). Data were log transformed in order
to meet the model assumptions of normality and homoscedasticity. Back-transformed esti-
mates and 95% confidence intervals are given. Significant results are in bold. (B) Linear mixed
effects models describing ESAT-6 and CFP-10. Outcome = a + b1  time + b2  group + b3 
(time  group). Data were log transformed in order to meet the model assumptions of normal-
ity and homoscedasticity. Back-transformed estimates and 95% confidence are given. Signifi-
cant results are in bold. (C) Linear mixed effects model describing the S/P ratio. Outcome = a
+ b1  time + b2  group + b3  (time  group). Data were log transformed in order to meet the
model assumptions of normality and homoscedasticity. Back-transformed estimates and 95%
confidence intervals are given. Significant results are in bold. (D) Double generalized linear
model describing ΔPPDB—ΔPPDA in the skin test. Outcome = a + b1  group. Estimates and
95% confidence intervals are given. Significant results are in bold. (E) A simple general linear
model describing ΔPC1 and ΔPC2. Outcome = a + b1  group. Estimates and 95% confidence
intervals are given. Significant results are in bold. (F) Linear mixed effects model describing
the PLN weights. Outcome = a + b1  LN side + b2  group + b3  (LN side  group) + b4  gen-
der. Data (PLN weights) were log transformed in order to meet the model assumptions of nor-
mality and homoscedasticity. Estimates and 95% confidence intervals are given. Significant
results are in bold. (G) Negative binomial generalized linear model describing the bacterial
counts. Outcome = a + b1  group. Back-transformed estimates and 95% confidence intervals
are given. Significant results are in bold.
(XLSX)
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